Microsoft (MSFT - Free Report) has a great track record of beating on earnings, so no one was surprised when the company did it again in July. It posted a strong fiscal fourth quarter with Commercial Cloud revenue up 39%, led by Azure up 64%. Office 365 now has 34.8 million subscribers and LinkedIn saw record engagement in the quarter. The company is only trading with a forward P/E of 26. It’s a Zacks Rank #2 (Buy) stock. [In full disclosure, Tracey owns shares of Microsoft in her personal portfolio.]
Cintas (CTAS - Free Report) beat on the fourth quarter and gave guidance for fiscal 2020 above the Zacks Consensus as the uniform rental business remains strong. It saw strength in healthcare, education and government. It has now posted 9 consecutive years of mid-single digit revenue growth. That’s impressive. Cintas shares are also breaking out to new multi-year highs on the news. It’s a Zacks Rank #2 (Buy) stock.
Should these two companies be on your investing short list? Find out in this week’s video.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>